Homeopathic Drug Product Safety, Quality, and Transparency Act
- Bill Number
- S. 4692
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-06-04: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-07-01T16:08:39Z
AI-Generated Summary
Purpose of the legislation This bill amends the Federal Food, Drug, and Cosmetic Act (FD&C Act) to create a dedicated statutory framework for homeopathic drug products. It aims to promote safety, quality, and transparency while recognizing their distinct preparation methods, risk profile, and historical regulatory treatment.
Key provisions outlined
- Definitions: Adds definitions for “homeopathic drug product” (a drug with only homeopathic ingredients) and “homeopathic ingredient” (listed in the Homeopathic Pharmacopoeia of the United States or prepared under recognized homeopathic standards).
- New regulatory section (503E): Establishes homeopathic drug products as a distinct category. Only FD&C Act sections 501 (adulteration), 502 (misbranding), 510 (registration), and 503E apply; they are exempt from section 505 new drug approval requirements.
- Safety and quality standards: Directs the Secretary of Health and Human Services to use standards appropriate to these products, including the Homeopathic Pharmacopoeia, without imposing unfeasible analytical methods.
- Manufacturing and testing rules: Requires a final rule within three years on current good manufacturing practices and labeling. Finished products are exempt from certain identity and strength testing but must meet contaminant standards. Intermediate testing is required for high-risk starting materials.
- Labeling and claims: Retail products must list intended uses for self-limiting conditions and include a disclaimer stating the uses have not been evaluated by the FDA. Claims must be supported by competent evidence, including traditional homeopathic principles, and must be preceded by “Traditionally used for.”
- Advisory committee: Creates a Homeopathic Drug Product Advisory Committee with balanced representation from practitioners, manufacturers, educators, and consumers. The committee advises on standards, guidance, and enforcement; the Secretary must consult it before major actions but is not required to follow its recommendations. The committee sunsets after seven years.
- Misbranding rules: Prohibits dietary supplements, non-homeopathic drugs, and cosmetics from using “homeopathic,” “homeopathy,” or similar terms on labeling.
- Conforming changes: Updates related provisions on drug supply chains, adverse event reporting, and biological products. Withdraws the FDA’s 2022 homeopathic guidance document.
Significant changes to existing law introduced
- Exempts homeopathic drug products from premarket approval under section 505 of the FD&C Act.
- Creates tailored good manufacturing practice and labeling requirements instead of applying standard drug rules.
- Establishes an advisory committee and mandatory consultation process for future FDA actions.
- Introduces specific misbranding prohibitions and removes the prior FDA guidance.
Potential impacts on government agencies, citizens, or international relations
- Government agencies: The FDA must issue a final rule within three years, establish and staff a new advisory committee, and update enforcement practices. Adverse event reporting systems will include homeopathic products.
- Citizens: Consumers may see clearer labeling with disclaimers and traditional-use claims, potentially increasing access to these products while providing more consistent safety oversight.
- International relations: No direct effects are specified in the bill.
Main stakeholders affected by this legislation
- Homeopathic drug manufacturers and distributors (large and small domestic producers).
- Licensed homeopathic practitioners and educators.
- Consumers of homeopathic products.
- The Food and Drug Administration and related advisory bodies.
- Organizations involved in homeopathic standards and pharmacopoeias.
Notable legal, constitutional, or political implications
- Provides explicit statutory authority for a separate regulatory pathway, reducing reliance on agency guidance.
- Balances consumer protection with recognition of traditional practices through evidence standards that include historical and real-world data.
- The advisory committee structure formalizes stakeholder input without binding the Secretary, preserving agency discretion.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2026-06-04: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2026-06-04: Introduced in Senate
Bill Versions
- Homeopathic Drug Product Safety, Quality, and Transparency Act — issued 2026-06-04 — PDF (12 pages)